Organon & Co. (NYSE:OGN) Receives $20.80 Average PT from Brokerages

Organon & Co. (NYSE:OGN) has been given a consensus rating of “Hold” by the seven brokerages that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $20.80.

Several analysts have issued reports on OGN shares. Morgan Stanley cut their target price on Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a research note on Friday, February 14th. Barclays cut their target price on Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. Finally, TD Cowen raised Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th.

Hedge Funds Weigh In On Organon & Co.

A number of institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of Organon & Co. by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 30,401,709 shares of the company’s stock valued at $453,593,000 after acquiring an additional 218,165 shares in the last quarter. Pacer Advisors Inc. increased its holdings in shares of Organon & Co. by 94,482.1% during the fourth quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company’s stock valued at $166,391,000 after acquiring an additional 11,140,388 shares in the last quarter. Massachusetts Financial Services Co. MA increased its holdings in shares of Organon & Co. by 1.4% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 9,895,067 shares of the company’s stock valued at $147,634,000 after acquiring an additional 136,760 shares in the last quarter. LSV Asset Management increased its holdings in shares of Organon & Co. by 0.4% during the fourth quarter. LSV Asset Management now owns 7,525,076 shares of the company’s stock valued at $112,274,000 after acquiring an additional 30,557 shares in the last quarter. Finally, Deprince Race & Zollo Inc. increased its holdings in shares of Organon & Co. by 7.0% during the fourth quarter. Deprince Race & Zollo Inc. now owns 4,729,258 shares of the company’s stock valued at $70,561,000 after acquiring an additional 308,267 shares in the last quarter. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Stock Up 2.1 %

OGN stock opened at $15.63 on Tuesday. Organon & Co. has a twelve month low of $13.87 and a twelve month high of $23.10. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. The firm has a market capitalization of $4.03 billion, a PE ratio of 4.69, a PEG ratio of 0.90 and a beta of 0.76. The stock has a 50-day simple moving average of $15.46 and a two-hundred day simple moving average of $16.60.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings data on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The business had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $1.57 billion. On average, equities analysts predict that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 13th. Shareholders of record on Monday, February 24th were issued a $0.28 dividend. The ex-dividend date was Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a yield of 7.17%. Organon & Co.’s dividend payout ratio (DPR) is 33.63%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.